Congestive heart failure in the elderly diabetic

Diabetes and Metabolism

Volumn 33, Issue SUPPL. 1, 2007, Pages

  Verny, C ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

Aging heart; Congestive heart failure; Diabetes mellitus; Diabetic heart disease; Diastolic dysfunction; Elderly diabetic

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLITAZONE DERIVATIVE; INSULIN SENSITIZING AGENT; METFORMIN; ORAL ANTIDIABETIC AGENT; STATINE DERIVATIVE; VALSARTAN;

AGING; ARTICLE; CHRONIC DISEASE; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIABETIC PATIENT; DIASTOLE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE COMPLIANCE; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IATROGENIC DISEASE; INSULIN RESISTANCE; PROGNOSIS; RISK FACTOR; SYMPTOMATOLOGY;

AGED; AGING; BLOOD GLUCOSE; DIABETIC ANGIOPATHIES; HEART FAILURE, CONGESTIVE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE;

EID: 34547938852     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)80055-3     Document Type: Article

References (61)

1. Kannel W., and McGee D. Diabetes and cardiovacular disease. The Framingham study. JAMA 24 (1979) 2035-2038
2. Pugh K., and Wei J. Clinical implications of physiological changes in the aging heart. Drugs Aging 18 (2001) 263-276
3. Baruch L., Glazer R., Aknay N., et al. Morbidity, mortality physiologic and functional parameters in elderly and non-elderly patients in the valsartan heart failure trial (Val-HeFT). Am Heart J 148 (2004) 951-957
4. Redfield M., Jacobsen S., Burnett Jr. J., Mahoney D., Bailey K., and Rodeheffer R. Burden of systolic and diastolic venticular dysfunction in the community: appreciating the scope of the heat failure epidemic. JAMA 289 (2003) 194-202
5. Cohen-Solal A., Desnos M., Delahaye F., Emerian J., and Hanania G. A national survey of heart failure in French hospitals. Eur Heart J 21 (2000) 763-769
6. Barker W., Mullooly J., and Getchell W. Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990-1994. Circulation 113 (2006) 799-805
7. Charbonnel B., Bouhanick B., and Le Feuvre C et le groupe de travail. Recommandations SFC/ALFEDIAM sur la prise en charge du patient diabétique vu par le cardiologue. Recommandations, argumentaire, références. Diabetes Metab 30 (2004) 2S2-2S24
8. Belmin J., and Friocourt P. Insuffisance cardiaque chronique du sujet âgé: l'apport des dernières recommandations de l'European Society of Cardiology. Revue de gériatrie 31 (2006) 359-368
9. Komajda M., Forette F., Aupetit J., et al. Recommandations pour le diagnostic et la prise en charge de l'insuffisance cardiaque du sujet âgé. Arch Mal Cœur 97 (2004) 803-821
10. California healthcare Foundation, and American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 51 (2003) S265-S280
11. Durso S. Using clinical guidelines designed for older adults with diabetes mellitus and complex health status. JAMA 295 (2006) 1935-1939
12. Nichols G., Hillier T., Erbey J., and Brown J. Congestive heart failure in type 2 diabetes. Diabetes Care 24 (2001) 1614-1619
13. Miyasaka Y., Barnes M., Gersh B., et al. Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: a community-based study over two decades. Eur Heart J 27 (2006) 936-941
14. Struthers A., and Morris A. Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet 359 (2002) 1430-1432
15. Solang L., Malmberg K., and Ryden L. Diabetes mellitus and congestive heart failure. Eur Heart J 20 (1999) 789-795
16. Huynh B., Rovner A., and Rich M. Long-term survival in elderly patients hospitalized for heart failure. 14-year follow-up from a prospective randomized trial. Arch Intern Med 166 (2006) 1892-1898
17. Gottdiener J., McClelland R., Marshal R., et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med 137 (2002) 631-639
18. Masoudi F., Baillie C., Wang Y., et al. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998-2001. Arch Intern Med 165 (2005) 2069-2076
19. Bhatia R., Tu J., Lee D., et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355 (2006) 260-269
20. Shekelle P., Rich M., Morton S., et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. J Am Coll Cardiol 41 (2003) 1529-1538
21. Olsson L., Swedberg K., Ducharme A., et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction. Results from the Candesartan in Heart failure-assessment of Reduction in Mortality and morbidity (CHARM) Program. J Am Coll Cardiol 47 (2006) 1997-2004
22. Stern S., Behar S., and Gottlieb S. Aging and diseases of the heart. Circulation 108 (2003) e99-e101
23. Blickle J. Management of hypertension in elderly diabetic patients. Diabetes Metab 31 (2005) 5S82-5S91
24. Bell D. Diabetic cardiomyopathy. Diabetes Care 26 (2003) 2949-2951
25. Ingelsson E., Sundström J., Arnlöv J., Zethelius B., and Lind L. Insulin resistance and risk of congestive heart failure. JAMA 29 (2005) 334-341
26. Bertoni A., Tsai A., Kasper E., and Brancati F. Diabetes and idiopathic cardiomyopathy. A nationwide case-control study. Diabetes Care 26 (2003) 2791-2795
27. Devereux R., Roman M., Paranicas M., et al. Impact of diabetes on cardiac structure and function. The strong heart study. Circulation 101 (2000) 2271-2276
28. Palmieri V., Bella J., Arnett D., et al. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects. Hypertension genetic epidemiology network (HyperGEN) study. Circulation 103 (2001) 102-107
29. Sundström J., Lind L., Nyström N., et al. Left ventricular concentric remodeling rather than left ventricular hypertrophy is related to the insulin resistance syndrome in elderly men. Circulation 101 (2000) 2595-2600
30. Rutter M., Parise H., Benjamin E., et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function. Circulation 107 (2003) 448-454
31. Lind L., Berne C., Andren B., and Lithell H. Relationship between diastolic hypertension and myocardial morphology and function in elderly males with diabetes mellitus. Diabetologia 39 (1996) 1603-1606
32. Van Heerebeek L., Borbély A., Niessen H., et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 113 (2006) 1966-1973
33. Candido R., Forbes J., Thomas M., et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 92 (2003) 785-792
34. Young M., McNulty P., and Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: Part II. Circulation 105 (2002) 1861-1870
35. Tsujino T., Kawasaki D., and Masuyama T. Left ventricular diastolic dysfunction in diabetic patients: pathophysiology and therapeutic implications. Am J Cardiovasc Drugs 6 (2006) 219-230
36. Poirier P., Bogaty P., Garneau C., Marois L., and Dumesnil J. Diastolic dysfunction in normotensive men with well-controled type 2 diabetes. Importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 24 (2001) 5-10
37. Ababsa R., Jourdain P., Sadeg N., Deschamps P., Jacoly C., and Funck F. Proposition d'un seuil de BNP discriminant dans la population très âgée présentant une insuffisance cardiaque. Ann Biol Clin 62 (2004) 437-440
38. Masoudi F., Havranek E., Smith G., et al. Gender, age and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 41 (2003) 217-223
39. Pocock S., Wang D., Pfeffer M., et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 27 (2006) 65-75
40. White H., Aylward P., Huang Z., et al. VALIANT investigators. Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction. Results from the Valsartan in Acute Myocardial Infarction Trial (VAL-IANT). Circulation 112 (2005) 3391-3399
41. Struthers A., Anderson G., Donnan P., and MacDonald T. Social deprivation increases cardiac hospitalisations in chronic heart failure independent of disease severity and diuretic non-adherence. Heart 83 (2000) 12-16
42. Havranck E., Abrams F., Stevens E., and Parker K. Deteninants of mortality in elderly patients with heart failure. The role of angiotensin-converting enzyme inhibitors. Arch Intern Med 158 (1998) 2024-2028
43. Smith N., Psaty B., Pitt B., Garg R., Gottdiener S., and Heckbert S. Temporal patterns in the medical treatment of congative heart failure with angiotensin-converting enzyme inhibitons in older adults, 1989 through 1995. Arch Intern Med 158 (1998) 1074-1080
44. Wang R., Mouliswar M., Denman S., and Kleban M. Morthy of the institutionalized old-old hospitalized with congestive heart failure. Arch Intern Med 158 (1998) 2464-2468
45. Erdmann E., Lechat P., Verkenne P., and Wiemann H. Resin from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 3 (2001) 469-479
46. Domanski M., Krause-Steinrauf H., Deedwania P., et al. The effect on diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol 42 (2003) 914-922
47. Foody J., Shah R., Galusha D., Masoudi F., Havatek E., and Krumholz H. Statins and mortality among elderly patients hospitalized with heart failure. Circulation 113 (2006) 1086-1092
48. Go A., Lee W., Yang J., Lo J., and Gurwitz J. Station therapy and risk for death and hospitalisation in chronic heart failure. JAMA 296 (2006) 2105-2111
49. Krum H., Bailey M., Meyer W., et al. Impact of stain therapy on clinical outcomes in chronic heart failure patients according to betablocker use: results of CIBIS II. Cardiology 108 (2006) 28-34
50. Khush K., and Waters D. Effects of statin therapy on the development and progression of heart failure: mechanisms and clinical trials. J Card Fail 12 (2006) 664-674
51. Kurian K., Rai P., Sankaran S., Jacob B., Chiong J., and Miller A. The effect of statins in heart failure: beyond its cholesterol-lowering effect. J Card Fail 12 (2006) 473-478
52. Ahmed A., Kiefe C., Allman R., Sims R., and DeLong J. Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications. J Am Geriatr Soc 50 (2002) 1659-1666
53. Yu C., and Sanderson J. Update in the management of diastolic heart failure. Curr Vasc Pharmacol 2 (2004) 301-308
54. Solomon S., Wang D., Finn P., et al. Effect of candesartan on causespecific mortality in heart failure patients. Circulation 110 (2004) 2180-2183
55. Yusuf S., Pfeffer M., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 362 (2003) 777-781
56. Piccini J., Klein L., Gheorghiade M., and Bonow R. New insights into diastolic heart failure: role of diabetes mellitus. Am J Med 116 (2004) 64-75
57. Constans T. Plasma glucose goals and therapeutic management in elderly diabetic patients. Diabetes Metab 31 (2005) 5S58-5S61
58. Nesto R., Bell D., Bonow R., et al. Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27 (2004) 256-263
59. Liu J., Robbins D., Palmieri V., et al. Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes. J Am Coll Cardiol 41 (2003) 2022-2028
60. Magnuson M., Melander O., Israelsson B., Grubb A., Groop L., and Jovinge S. Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care 27 (2004) 1929-1935
61. Beer S., Golay S., Bardy D., et al. Increased plasma levels of N-terminal brain natriuretic peptide (Nt-proBNP) in type 2 diabetic patients with vascular complications. Diabetes Metab 31 (2005) 567-573